Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / RPTX - Dosing underway in Repare Therapeutics' Phase 1 trial of RP-6306 in solid tumors

RPTX - Dosing underway in Repare Therapeutics' Phase 1 trial of RP-6306 in solid tumors

Repare Therapeutics Inc.
Repare Therapeutics (RPTX -0.3%) announces the first patient has been dosed in its Phase 1 clinical trial of RP-6306, in combination with gemcitabine for the treatment of molecularly selected advanced solid tumors (the MAGNETIC trial). MAGNETIC will assess the safety and tolerability of RP-6306 in combination with gemcitabine, and will enroll ~104 patients with tumors harboring genomic alterations. This multicenter Phase 1 study aims to determine the maximum tolerated dose, identify a recommended phase 2 dose and preferred schedule, and assess preliminary anti-tumor activity. Further updates on RP-6306 are anticipated later in 2022.

For further details see:

Dosing underway in Repare Therapeutics' Phase 1 trial of RP-6306 in solid tumors
Stock Information
Company Name: Repare Therapeutics Inc.
Stock Symbol: RPTX
Market: NASDAQ
Website: reparerx.com
Menu
RPTX RPTX Quote RPTX Short RPTX News RPTX Articles RPTX Message Board
Get RPTX Alerts

News, Short Squeeze, Breakout and More Instantly...